CoChat

Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation

Open access

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index; none of the 101 sources its claims cite is checked for support yet.

Abstract

Chimeric antigen receptor (CAR) T cells offer a promising strategy for the treatment of autoimmune diseases. However, clinical translation is limited by the high cost, complexity, and poor scalability of current manufacturing, restricting broad patient access and persisting safety concerns including insertional mutagenesis risk from integrating vectors and uncontrolled long-term CAR T cell persistence. In-vitro -transcribed (IVT) mRNA enables transient, non-integrating CAR expression with improved safety and scalability, making it particularly suited for non-malignant indications where prolonged persistence may not be required. Here, we systematically compare two IVT mRNA delivery platforms, electroporation and lipid nanoparticles (LNPs), for transient CAR T cell engineering in primary human T cells using single-cell transcriptomics and functional cell assays. We show that electroporation yields higher transfection efficiency and more sustained CAR surface expression, whereas LNP delivery reduces stress- and senescence-related transcriptional signatures as well as exhaustion marker expression, while enhancing antigen-driven activation, chemotactic responses, and cytotoxic function. Our comparative analysis highlights that the mode of mRNA delivery is associated with distinct transcriptional signatures and functional properties of CAR T cells, providing a framework to guide future development of mRNA-based approaches. These insights support LNP-mediated delivery as a functionally favorable strategy for transient CAR T cell engineering in autoimmune disease and beyond.

Overview

CoChat Summary

TL;DR

In primary human T cells, LNP-mediated IVT mRNA delivery produced lower CAR expression than electroporation but preserved cytotoxicity, improved migration, and reduced exhaustion/stress signatures. Electroporation achieved higher transfection and CAR density but induced stress, DNA damage, senescence, and exhaustion-associated programs.

Key findings

  • Electroporation achieved >95% CD19-CAR+ T cells at 24 h and ∼4 × 10⁴ CD19-CAR molecules per cell, whereas LNP delivery reached ∼65% and ∼3 × 10³ molecules per cell; both peaked at 24 h, with detectable CAR for 4 days (electroporation) versus 3 days (LNP).
  • Despite lower CAR expression, LNP-transfected CAR T cells achieved comparable target-cell killing and trended toward enhanced per-cell cytotoxicity; they also showed lower TIM-3 and LAG-3 across CD3+, CD4+, and CD8+ subsets, while PD-1 was unaffected, and trended toward improved CCL21 migration.
  • scRNA-seq of 10,883 high-quality transcriptomes identified an electroporation-specific CD4+ cluster (cluster 8; 4.48%–16.2% of electroporated CD19-CAR T cells) enriched for ER stress, unfolded protein response, and DNA damage genes including TRIB3, DDIT3, CCPG1, SESN2, DNAJB9, and ATF3; LNP-transfected cells primarily activated interferon-stimulated genes such as IFI44L, MX1, IFI6, DDX60, RSAD2, XAF1, IRF7, and USP18 without stress or apoptotic signatures.
  • IVT mRNA multiplexing via electroporation yielded >85% CD19-CAR+ T cells at 8 h and >95% at 24 h; CD19-CAR + CCR7 co-transfection gave a median 78.20% CD19-CAR+ T cells, four-mRNA delivery gave ∼90% CD19-CAR+GFP+ cells at 8 h, and CCR7 mRNA rescued migratory and cytotoxic function in CCR7 knockout T cells.

Methods

  • Primary human T cells from healthy donors were isolated from PBMCs, CD3+ enriched by MACS, and polyclonally activated with plate-bound anti-CD3/CD28 for 48 h; on day 3, IVT mRNA encoding CD19-CAR, CCR7, CXCR3, or GFP was delivered by electroporation (Lonza 4D-Nucleofector, program EO-115) or LNP (GenVoy-ILM T-cell kit with ApoE), with mock and untouched controls.
  • Functional readouts included transwell migration toward CCL21, live-cell imaging cytotoxicity against NALM6 and Raji target cells, serial killing assays, flow cytometry for activation/exhaustion/cytokines, Luminex cytokine analysis, and targeted scRNA-seq at 24 h post-transfection using 10× Genomics 5′ v2 with hashtag demultiplexing, Seurat clustering, DESeq2 pseudobulk differential expression, and GO module scores.
  • Statistical analyses used paired t tests, one-way ANOVA with Tukey’s post hoc test, Friedman test with Dunn’s multiple comparison, two-way repeated-measures ANOVA with Šidák’s multiple-comparison test, and Pearson/Spearman correlation, with n = 3–8 independent donors depending on the assay.

Limitations

  • Stated in the paper: results were obtained from a single LNP formulation; differences across electroporation platforms may prevent complete generalization of electroporation-induced phenotypes; the study focused exclusively on ex vivo delivery; direct assessment of persistence and long-term function in advanced animal disease models is still needed; and inter-donor variability was noted in the magnitude of CCR7-mediated killing effects.
  • Evident from the text: the work is an in vitro study using healthy-donor T cells with small donor numbers (n = 3–8 across assays), without autoimmune patient samples or in vivo disease models, so clinical translation to persistence, safety, and therapeutic efficacy remains untested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2026.102929

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
Figure 1 Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, CD3+ T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com. (B and C) Flow cytometric analysis of CD19-CAR+ frequency (B) and CD19-CAR molecules per cell (C) in CD3+, CD4+, and CD8+ T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com. (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR+ frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3+ T cells, 8 h after mRNA transfection (n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com. (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR+ GFP+ double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection (n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.
Figure 1 Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, CD3+ T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com. (B and C) Flow cytometric analysis of CD19-CAR+ frequency (B) and CD19-CAR molecules per cell (C) in CD3+, CD4+, and CD8+ T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com. (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR+ frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3+ T cells, 8 h after mRNA transfection (n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com. (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR+ GFP+ double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection (n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.CC BY · PubMed Central
Figure 2 Co-transfection of CCR7 with CD19-CAR T cells enhances migration toward a lymph node-associated chemokine (A) Schematic showing the concept of improving CD19-CAR T cell migration toward CCL21 by co-transfecting CCR7 mRNA alongside CD19-CAR mRNA (lower) compared to conventional CD19-CAR T cells (upper). Created with BioRender.com. (B) Chemotactic index toward CCL21 for mock-transfected, CCR7-only, CD19-CAR-only, and CD19-CAR + CCR7 co-transfected T cells. The chemotactic index was calculated as the ratio of migrated cells in the presence versus absence of CCL21, quantified by flow cytometry. (C) Correlation between CCR7 expression level and migration. Scatterplot showing the relationship between CCR7 geometric mean fluorescence intensity and chemotactic index in CD19-CAR T cells. Pearson’s r and p values are indicated. (D) Experimental workflow: single- or co-transfected T cells were assessed in an in vitro transwell assay, first migrating toward CCL21 for 3 h, followed by co-culture with NALM6 target cells (CD19+ and GFP+). Killing efficiency was monitored over 28 h with 4-h intervals using live-cell imaging. Created with BioRender.com. (E) Killing kinetics after CCL21-mediated migration. Time-course analysis of cytotoxicity against NALM6 target cells by untouched, mock-transfected, CCR7-only, CD19-CAR-only, and CD19-CAR + CCR7 co-transfected T cells over 28 h. Data represent mean ± SD from n = 4 independent donors. (F) Area under the curve (AUC) analysis of total killing capacity over the 28 h observation period for the same groups. Data represent mean ± SD from n = 4 independent donors. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test (B) or Friedman test followed by Dunn’s multiple comparison test (F). ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from n = 8 independent donors, unless stated otherwise.
Figure 2 Co-transfection of CCR7 with CD19-CAR T cells enhances migration toward a lymph node-associated chemokine (A) Schematic showing the concept of improving CD19-CAR T cell migration toward CCL21 by co-transfecting CCR7 mRNA alongside CD19-CAR mRNA (lower) compared to conventional CD19-CAR T cells (upper). Created with BioRender.com. (B) Chemotactic index toward CCL21 for mock-transfected, CCR7-only, CD19-CAR-only, and CD19-CAR + CCR7 co-transfected T cells. The chemotactic index was calculated as the ratio of migrated cells in the presence versus absence of CCL21, quantified by flow cytometry. (C) Correlation between CCR7 expression level and migration. Scatterplot showing the relationship between CCR7 geometric mean fluorescence intensity and chemotactic index in CD19-CAR T cells. Pearson’s r and p values are indicated. (D) Experimental workflow: single- or co-transfected T cells were assessed in an in vitro transwell assay, first migrating toward CCL21 for 3 h, followed by co-culture with NALM6 target cells (CD19+ and GFP+). Killing efficiency was monitored over 28 h with 4-h intervals using live-cell imaging. Created with BioRender.com. (E) Killing kinetics after CCL21-mediated migration. Time-course analysis of cytotoxicity against NALM6 target cells by untouched, mock-transfected, CCR7-only, CD19-CAR-only, and CD19-CAR + CCR7 co-transfected T cells over 28 h. Data represent mean ± SD from n = 4 independent donors. (F) Area under the curve (AUC) analysis of total killing capacity over the 28 h observation period for the same groups. Data represent mean ± SD from n = 4 independent donors. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test (B) or Friedman test followed by Dunn’s multiple comparison test (F). ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from n = 8 independent donors, unless stated otherwise.CC BY · PubMed Central
Figure 3 Comparison of CD19-CAR expression kinetics using electroporation versus lipid nanoparticle delivery (A) Schematic illustration of IVT mRNA delivery mechanisms: electroporation (EP)-mediated delivery of naked IVT mRNA through transient membrane permeabilization versus lipid nanoparticle (LNP)-encapsulated IVT mRNA uptake via endocytosis, both leading to CD19-CAR protein translation. (B) Representative flow cytometry plots showing CD19-CAR expression in mock-transfected and mRNA-transfected T cells 24 h post-transfection, for electroporation (upper) and LNP delivery (lower). (C and D) Flow cytometric analysis of CD19-CAR+ frequency (C) and CD19-CAR molecules per cell (D) over 96 h after mRNA delivery by electroporation or LNPs. (E) Correlation between CD19-CAR+ frequency and CD19-CAR molecules per cell. (F) Representative flow cytometry plots showing annexin V and live/dead staining in mock-transfected and CD19-CAR mRNA-transfected T cells 4, 8 and 24 h post-transfection, for electroporation (upper) and LNP delivery (lower). (G) Flow cytometric analysis of annexin V+ and dead cell frequency in mock-transfected and mRNA-transfected T cells (EP or LNP) over 24 h comparing electroporation and LNP-transfection as IVT mRNA delivery methods. (H) Flow cytometric analysis of T cell viability, assessed by live/dead staining over 96 h post-transfection. Statistical analysis for differences between groups was performed by two-way repeated-measures ANOVA with Šidák’s multiple-comparison test. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SEM from n = 4 independent donors.
Figure 3 Comparison of CD19-CAR expression kinetics using electroporation versus lipid nanoparticle delivery (A) Schematic illustration of IVT mRNA delivery mechanisms: electroporation (EP)-mediated delivery of naked IVT mRNA through transient membrane permeabilization versus lipid nanoparticle (LNP)-encapsulated IVT mRNA uptake via endocytosis, both leading to CD19-CAR protein translation. (B) Representative flow cytometry plots showing CD19-CAR expression in mock-transfected and mRNA-transfected T cells 24 h post-transfection, for electroporation (upper) and LNP delivery (lower). (C and D) Flow cytometric analysis of CD19-CAR+ frequency (C) and CD19-CAR molecules per cell (D) over 96 h after mRNA delivery by electroporation or LNPs. (E) Correlation between CD19-CAR+ frequency and CD19-CAR molecules per cell. (F) Representative flow cytometry plots showing annexin V and live/dead staining in mock-transfected and CD19-CAR mRNA-transfected T cells 4, 8 and 24 h post-transfection, for electroporation (upper) and LNP delivery (lower). (G) Flow cytometric analysis of annexin V+ and dead cell frequency in mock-transfected and mRNA-transfected T cells (EP or LNP) over 24 h comparing electroporation and LNP-transfection as IVT mRNA delivery methods. (H) Flow cytometric analysis of T cell viability, assessed by live/dead staining over 96 h post-transfection. Statistical analysis for differences between groups was performed by two-way repeated-measures ANOVA with Šidák’s multiple-comparison test. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SEM from n = 4 independent donors.CC BY · PubMed Central
Figure 4 Memory phenotype characterization of IVT mRNA-transfected CD19-CAR T cells (A) Representative flow cytometry plots showing the gating strategy for CD8+ memory T cell subsets in primary human CD3+-enriched T cells. Subsets were defined by CD3+, CD4–, CD8+, and CCR7/CD45RA expression as follows: naive like (Tnaive like; CCR7+ CD45RA+), central memory (TCM; CCR7+ CD45RA–), effector memory (TEM; CCR7– CD45RA–), and terminally differentiated effector (TEMRA; CCR7– CD45RA+). (B) Frequencies of CD4+ and CD8+ T cells within CD19-CAR+ populations compared with mock-transfected controls after electroporation or LNP transfection. (C and D) Geometric mean fluorescence intensity (gMFI) of CD19-CAR expression in bulk CD4+ (C) and CD8+ (D) T cell populations following electroporation or LNP-mediated transfection; representative experiment. (E and F) CD19-CAR surface expression across memory T cell subsets within the CD8+ population following electroporation (E) or LNP-mediated (F) mRNA delivery over 108 h post-transfection. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test (B) or by two-way repeated-measures ANOVA with Šidák’s multiple-comparison test (E and F). ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from n = 4 independent donors, unless stated otherwise.
Figure 4 Memory phenotype characterization of IVT mRNA-transfected CD19-CAR T cells (A) Representative flow cytometry plots showing the gating strategy for CD8+ memory T cell subsets in primary human CD3+-enriched T cells. Subsets were defined by CD3+, CD4–, CD8+, and CCR7/CD45RA expression as follows: naive like (Tnaive like; CCR7+ CD45RA+), central memory (TCM; CCR7+ CD45RA–), effector memory (TEM; CCR7– CD45RA–), and terminally differentiated effector (TEMRA; CCR7– CD45RA+). (B) Frequencies of CD4+ and CD8+ T cells within CD19-CAR+ populations compared with mock-transfected controls after electroporation or LNP transfection. (C and D) Geometric mean fluorescence intensity (gMFI) of CD19-CAR expression in bulk CD4+ (C) and CD8+ (D) T cell populations following electroporation or LNP-mediated transfection; representative experiment. (E and F) CD19-CAR surface expression across memory T cell subsets within the CD8+ population following electroporation (E) or LNP-mediated (F) mRNA delivery over 108 h post-transfection. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test (B) or by two-way repeated-measures ANOVA with Šidák’s multiple-comparison test (E and F). ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from n = 4 independent donors, unless stated otherwise.CC BY · PubMed Central
Figure 5 Single-cell transcriptional response of CD19-CAR T cells transfected with electroporation or LNP (A) UMAP embeddings of donor-integrated scRNA-seq data showing 10,883 high-quality transcriptomes annotated as CD4+ or CD8+ T cells, colored by T cell subtype, transfection method and leiden clustering. (B and C) Module scores of curated GO term gene sets in CD4+ (B) and CD8+ (C) T cell subsets. Median module scores per donor are plotted. (D and E) Volcano plot of differentially expressed genes (DEGs) between LNP and EP transfected CD4+ (D) and CD8+ (E) T cells. DE testing was performed using a paired pseudobulk approach using DESeq2. Datapoints for genes with baseMean >50 are plotted, log2FoldChange threshold set to 0.5 (CD4+) and 0.3 (CD8+), adjusted p value threshold set to 0.05. Top 15 DEG according to Log2FoldChange above both thresholds are labeled. (F) Dotplot of top 40 upregulated DEG of cluster 8 vs. all other cluster. DE testing was performed using a paired pseudobulk approach using DESeq2. Genes with baseMean >50 and adjusted p value <0.05 were ranked according to log2FoldChange. (G) GO enrichment analysis of the top upregulated DEG of cluster 8 vs. all other cluster. Genes with baseMean >50 and adjusted p value <0.05 were considered and top 50 according to log2FoldChange were used as input. (B and C) Boxplots showing median and lower and upper hinges correspond to the first and third quartiles. Upper and lower whisker extends from the hinge to the largest/smallest value no further than 1.5 ∗ IQR from the hinge. Data beyond the end of the whiskers are plotted individually. Statistical comparisons of median module scores across groups were performed using the Kruskal-Wallis test, followed by Dunn’s post hoc test with Holm adjustment for multiple testing. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represents data from n = 5 independent donors.
Figure 5 Single-cell transcriptional response of CD19-CAR T cells transfected with electroporation or LNP (A) UMAP embeddings of donor-integrated scRNA-seq data showing 10,883 high-quality transcriptomes annotated as CD4+ or CD8+ T cells, colored by T cell subtype, transfection method and leiden clustering. (B and C) Module scores of curated GO term gene sets in CD4+ (B) and CD8+ (C) T cell subsets. Median module scores per donor are plotted. (D and E) Volcano plot of differentially expressed genes (DEGs) between LNP and EP transfected CD4+ (D) and CD8+ (E) T cells. DE testing was performed using a paired pseudobulk approach using DESeq2. Datapoints for genes with baseMean >50 are plotted, log2FoldChange threshold set to 0.5 (CD4+) and 0.3 (CD8+), adjusted p value threshold set to 0.05. Top 15 DEG according to Log2FoldChange above both thresholds are labeled. (F) Dotplot of top 40 upregulated DEG of cluster 8 vs. all other cluster. DE testing was performed using a paired pseudobulk approach using DESeq2. Genes with baseMean >50 and adjusted p value <0.05 were ranked according to log2FoldChange. (G) GO enrichment analysis of the top upregulated DEG of cluster 8 vs. all other cluster. Genes with baseMean >50 and adjusted p value <0.05 were considered and top 50 according to log2FoldChange were used as input. (B and C) Boxplots showing median and lower and upper hinges correspond to the first and third quartiles. Upper and lower whisker extends from the hinge to the largest/smallest value no further than 1.5 ∗ IQR from the hinge. Data beyond the end of the whiskers are plotted individually. Statistical comparisons of median module scores across groups were performed using the Kruskal-Wallis test, followed by Dunn’s post hoc test with Holm adjustment for multiple testing. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represents data from n = 5 independent donors.CC BY · PubMed Central
Figure 6 Functional characterization of CD19-CAR mRNA transfected T cells following antigen encounter (A) Experimental workflow of the overnight stimulation assay: mock-transfected and mRNA-transfected CD19-CAR T cells were stimulated with NALM6 (CD19+) cells for 16 h in the presence of brefeldin A to capture intracellular cytokine production by flow cytometry. Created with BioRender.com. (B) Representative flow cytometry plots showing activation marker expression (CD137 and CD154) in CD3+ T cells with (stimulated) and without (unstimulated) target cell stimulation. Comparisons are shown for electroporated (left) and LNP-transfected (right) CD19-CAR T cells. (C) Frequencies of activated (CD137+ and/or CD154+) CD3+, CD4+, and CD8+ T cell populations, comparing electroporation and LNP delivery methods. Data are background-subtracted. (D) Intracellular effector cytokine production (IFN-γ and TNF-α) within activated CD3+, CD4+, and CD8+ T cell populations. Data showing the relative increase in cytokine-producing T cells for LNP transfection normalized to electroporation. Statistical analysis was performed by paired t test. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from n = 4 independent donors.
Figure 6 Functional characterization of CD19-CAR mRNA transfected T cells following antigen encounter (A) Experimental workflow of the overnight stimulation assay: mock-transfected and mRNA-transfected CD19-CAR T cells were stimulated with NALM6 (CD19+) cells for 16 h in the presence of brefeldin A to capture intracellular cytokine production by flow cytometry. Created with BioRender.com. (B) Representative flow cytometry plots showing activation marker expression (CD137 and CD154) in CD3+ T cells with (stimulated) and without (unstimulated) target cell stimulation. Comparisons are shown for electroporated (left) and LNP-transfected (right) CD19-CAR T cells. (C) Frequencies of activated (CD137+ and/or CD154+) CD3+, CD4+, and CD8+ T cell populations, comparing electroporation and LNP delivery methods. Data are background-subtracted. (D) Intracellular effector cytokine production (IFN-γ and TNF-α) within activated CD3+, CD4+, and CD8+ T cell populations. Data showing the relative increase in cytokine-producing T cells for LNP transfection normalized to electroporation. Statistical analysis was performed by paired t test. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SD from n = 4 independent donors.CC BY · PubMed Central
Figure 7 Functional characterization of CD19-CAR T cells produced by LNP-mediated versus electroporation-based mRNA delivery (A) Experimental workflow: electroporated and LNP-transfected T cells were assessed in an in vitro transwell assay, first migrating toward CCL21 for 3 h, followed by co-culture with NALM6 target cells (CD19+ GFP+). Killing efficiency was monitored over 28 h with 4-h intervals using live-cell imaging. Created with BioRender.com. (B) Killing efficacy of NALM6 (CD19+ GFP+) target cells using untouched, mock-transfected and CD19-CAR mRNA transfected T cells (EP and LNP) over 28 h assessed using live-cell imaging every 4 h. (C) Area under the curve (AUC) analysis of total killing capacity over the 28-h observation period for the same groups relative to untouched T cells. (D) Fold increase of migrated CD3+ T cells toward CCL21 chemokine normalized to untouched T cells comparing LNP and electroporation delivery methods for mock-transfected and CD19-CAR mRNA transfected T cells analyzed using flow cytometry. (E) Flow cytometric analysis of exhaustion marker expression (TIM-3 and LAG-3) in CD3+, CD4+ and CD8+ T cell populations following cytotoxic activity of LNP-transfected T cells normalized to electroporated T cells. (F) Mean percentage of CAR T cells expressing zero, one, two, or three exhaustion markers in electroporated T cells (upper) and LNP-transfected CD19-CAR T cells (lower) following cytotoxic activity. (G) Supernatants from migrated T cell killing assays were collected and analyzed for pro-inflammatory cytokines. Mean levels of granzyme B, IFN-γ, TNF-α, IL-8, and IL-10 are shown. Normalized to CD19-CAR frequency for each sample. Statistical analysis for differences between subpopulations was performed by Friedman test followed by Dunn’s multiple comparison test (C, D, and G) or paired t test (E). ∗ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SEM from n = 4 independent donors.
Figure 7 Functional characterization of CD19-CAR T cells produced by LNP-mediated versus electroporation-based mRNA delivery (A) Experimental workflow: electroporated and LNP-transfected T cells were assessed in an in vitro transwell assay, first migrating toward CCL21 for 3 h, followed by co-culture with NALM6 target cells (CD19+ GFP+). Killing efficiency was monitored over 28 h with 4-h intervals using live-cell imaging. Created with BioRender.com. (B) Killing efficacy of NALM6 (CD19+ GFP+) target cells using untouched, mock-transfected and CD19-CAR mRNA transfected T cells (EP and LNP) over 28 h assessed using live-cell imaging every 4 h. (C) Area under the curve (AUC) analysis of total killing capacity over the 28-h observation period for the same groups relative to untouched T cells. (D) Fold increase of migrated CD3+ T cells toward CCL21 chemokine normalized to untouched T cells comparing LNP and electroporation delivery methods for mock-transfected and CD19-CAR mRNA transfected T cells analyzed using flow cytometry. (E) Flow cytometric analysis of exhaustion marker expression (TIM-3 and LAG-3) in CD3+, CD4+ and CD8+ T cell populations following cytotoxic activity of LNP-transfected T cells normalized to electroporated T cells. (F) Mean percentage of CAR T cells expressing zero, one, two, or three exhaustion markers in electroporated T cells (upper) and LNP-transfected CD19-CAR T cells (lower) following cytotoxic activity. (G) Supernatants from migrated T cell killing assays were collected and analyzed for pro-inflammatory cytokines. Mean levels of granzyme B, IFN-γ, TNF-α, IL-8, and IL-10 are shown. Normalized to CD19-CAR frequency for each sample. Statistical analysis for differences between subpopulations was performed by Friedman test followed by Dunn’s multiple comparison test (C, D, and G) or paired t test (E). ∗ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Data represent mean ± SEM from n = 4 independent donors.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 36 Not checked · 105 Own results and interpretations

60 more claims

Create a free account to see all 141 claims and to verify the 101 references still open.

See all claims — free account
  • It may state two separate claims as one. 65
  • Probably not a substantial claim. 21
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 78 references

Cited by

See all 7

Metadata

Authors
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., Krönke, G., Pichon, C., Sander, L. E., Volk, H.-D., Gossen, M., Schmueck-Henneresse, M., & Drzeniek, N. M.
Affiliations
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
  • Humboldt-Universität zu Berlin (DE)
  • German Rheumatism Research Centre (DE)
  • Université d'Orléans (FR)
  • Helmholtz-Zentrum Hereon (DE)
Corresponding author
Drzeniek, Norman M.
Venue
Molecular Therapy Nucleic Acids
Publisher
Elsevier BV
Published
2026-06
Volume
37
Issue
2
Pages
102929
ISSN
2162-2531 (ISSN-L)
OpenAlex
W7151581709
Cited by
7
References
78
Citations by year
2026: 7
FWCI
14.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy — Nucleic Acids (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
Funders
  • Federal Ministry of Education and Research Bonn Office
  • Horizon Europe (101156595)
  • Berlin-Brandenburger Centrum für Regenerative Therapien
  • Stiftung Charité
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chimeric antigen receptor T cells, lipid nanoparticles, electroporation, in vitro transcribed mRNA, CAR-T cell exhaustion, cytotoxicity, CAR-T cell engineering, autoimmune disease, transfection efficiency, senescence, chemotaxis, single-cell transcriptomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation. https://app.cochat.ai/papers/10.1016/j.omtn.2026.102929
The paper
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., Krönke, G., Pichon, C., Sander, L. E., Volk, H.-D., Gossen, M., Schmueck-Henneresse, M., & Drzeniek, N. M. (2026). Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation. Molecular Therapy Nucleic Acids. https://doi.org/10.1016/j.omtn.2026.102929

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.